不同剂量环硅酸锆钠散治疗血液透析患者非透析日高钾血症的疗效

目的观察不同剂量环硅酸锆钠散(SZC)治疗血液透析患者非透析日高钾血症疗效及安全性。方法回顾性分析2022年1月至2023年1月181例血液透析伴非透析日高钾血症患者的临床资料,按SZC不同治疗剂量分为低剂量组和高剂量组,监测两组患者服药后6 h、12 h及24 h的静脉血钾及不良反应。结果两组SZC治疗后6 h血钾水平比较,差异无统计学意义(P>0.05)。两组SZC治疗后12 h、24 h血钾水平比较,差异有统计学意义(P<0.05)。两组服药后24h不良反应比较,差异无统计学意义(P>0.05)。结论服不同剂量SZC后6h均有较好的降钾作用,但降钾幅度无差异;服高剂量SZC后12h、24h仍有较好的降钾作用。

Objective To observe the efficacy and safety of different doses of sodium zirconium cyclic silicate in the treatment of non-dialysis day hyperkalemia in hemodialysis patients.Methods A retrospective analysis of 181 patients with hyperkalemia on hemodialysis from January 2022 to January 2023 was performed.Patients treated with different doses of zirconium silicate sodium powder treatment were divided into the low-dose group and the highdose group.The venous potassium and adverse reactions were monitored for 6 h,12 h and 24 h after taking the drug in both groups.Results The difference in potassium levels between the two groups at 6 h after SZC treatment was not statistically significant(P>0.05).Comparison of blood potassium levels at 12 h and 24 h after SZC treatment between the two groups,the difference was statistically significant(P<0.05).Comparison of adverse reactions 24 h after taking SZC between the two groups,the difference was not statistically significant(P>0.05).Conclusion Different dose of SZC has good potassium lowering effect 6 h later,but there is no difference in potassium reduction amplitude,high-dose SZC still has good potassium lowering effect at 12 h and 24 h.